IPP Bureau
Lupin launches nasal spray in US
By IPP Bureau - July 04, 2025
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen US footprint
By IPP Bureau - July 03, 2025
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy
By IPP Bureau - July 03, 2025
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
WuXi XDC announces mechanical completion of Singapore site
By IPP Bureau - July 03, 2025
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer
By IPP Bureau - July 03, 2025
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Mitsui Chemicals launches InnoCell cell Culture microplates with exceptional oxygen permeability
By IPP Bureau - July 03, 2025
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
India exports US$ 4,961 million pharmaceutical during April–May 2025: Pharmexcil
By IPP Bureau - July 02, 2025
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Cadila Pharmaceuticals launches Bilacad Dex Syrup
By IPP Bureau - July 02, 2025
A triple-action Formula for comprehensive respiratory relief
Lupin carves out LupinLife Consumer Healthcare
By IPP Bureau - July 02, 2025
AstraZeneca Pharma India receives permission to import Durvalumab Solution
By IPP Bureau - July 02, 2025
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Gel
By IPP Bureau - July 02, 2025
Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery
INmune Bio reports core findings from Phase 2 trial in early Alzheimer’s disease
By IPP Bureau - July 02, 2025
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Glaukos receives EU MDR certification for iStent infinite
By IPP Bureau - July 02, 2025
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
AbbVie to acquire Capstan Therapeutics for $2.1 billion
By IPP Bureau - July 01, 2025
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer
By IPP Bureau - July 01, 2025
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
